Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DME2PY5)

• Drug Name: Midodrine Drug Info
• Synonyms: Alphamine; Amatine; Gutron; Hipertan; Metligene; Midamine; Midodrin; Midodrina; Midodrinum; ProAmatine; MIDODRINE HYDROCHLORIDE; Midodrine HCL; Midodrine Monohydrochloride; Midodrine hydrochloride [USAN]; A 4020 Linz; St 1085; TS 701; A-4020 Linz; Midodrina [INN-Spanish]; Midodrine (INN); Midodrine [BAN:INN]; Midodrine [INN:BAN]; Midodrine hydrochloride [USAN:JAN]; Midodrinum [INN-Latin]; Pro-Amatine; Proamatine (TN); ST-1085; St. Peter 224; Midodrine hydrochloride (JAN/USAN); Pro-Amatine (TN); DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid; N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]glycinamide; N-{2-[2,5-bis(methyloxy)phenyl]-2-hydroxyethyl}glycinamide; [+/-]-1-[2,5-Dimethoxyphenyl]-2-glycinamidoethanol; Acetamide, 2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)-, hydrochloride; Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-, monohydrochloride; (+-)-1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; (+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide monohydrochloride; (+-)-Midodrine hydrochloride; (+/-)-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; (-)-Midodrin hydrochloride; (-)-Midodrine hydrochloride; (RS)-N'-(beta-Hydroxy-2,5-dimethoxy-phenethyl)glycinamid; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; 1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamid; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethylacetamide; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide monohydrochloride; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hyyroxyethyl)acetamide monohydrochloride; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide hydrochloride
• Therapeutic Class: Vasoconstrictor Agents
• Cross-matching ID:
  PubChem CID: 4195
  ChEBI ID: CHEMBL6933
  CAS Number: CAS 42794-76-3
  TTD Drug ID: D02XJY
  VARIDT Drug ID: DR01164
  INTEDE Drug ID: DR1088
  ACDINA Drug ID: D00430

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Retinol metabolism	2.18	0.00e+0	41/68 (60.29%)	CYP2C9;CYP2A6;CYP3A4;...
Complement and coagulation cascades	1.88	2.35e-2	76/85 (89.41%)	A2M;SERPINA1;C4BPA;...
Metabolism of xenobiotics by cytochrome P450	1.88	1.56e-2	49/77 (63.64%)	CYP2C9;CYP2A6;CYP3A4;...
Ascorbate and aldarate metabolism	1.86	1.17e-2	15/30 (50%)	UGDH;UGT2B15;UGT2A3;...
Pentose and glucuronate interconversions	1.84	1.25e-2	17/34 (50%)	SORD;UGDH;UGT2B15;...
Bile secretion	1.79	2.08e-2	68/90 (75.56%)	KCNN2;CYP3A4;SLC22A1;...
Homologous recombination	1.78	2.23e-2	35/41 (85.37%)	BARD1;BRIP1;BLM;...
Tryptophan metabolism	1.75	3.23e-2	35/42 (83.33%)	MAOB;AOC1;KMO;...
Drug metabolism	1.74	3.13e-2	78/151 (51.66%)	MAOB;CYP2C9;CYP2A6;...
Terpenoid backbone biosynthesis	1.70	3.60e-2	18/22 (81.82%)	HMGCS1;ICMT;GGPS1;...
Fanconi anemia pathway	1.69	3.84e-2	36/54 (66.67%)	REV3L;BRIP1;BLM;...
DNA replication	1.69	3.58e-2	34/36 (94.44%)	POLE2;DNA2;RFC5;...
Cell cycle	1.65	4.69e-2	110/124 (88.71%)	CCNB2;CDC45;CDC25B;...
Phagosome	-1.68	4.85e-2	118/152 (77.63%)	ITGB1;NCF2;HLA-G;...
Focal adhesion	-1.70	4.08e-2	180/201 (89.55%)	TLN2;ROCK2;DOCK1;...
Autophagy	-1.70	4.37e-2	113/169 (66.86%)	GABARAPL1;PPP2CB;STK11;...
Collecting duct acid secretion	-1.70	4.85e-2	22/27 (81.48%)	ATP6V0C;CLCNKB;ATP6V1A;...
TGF-beta signaling pathway	-1.73	4.85e-2	81/94 (86.17%)	TGFB1;CDKN2B;SMURF1;...
Mitophagy	-1.77	2.77e-2	56/68 (82.35%)	PINK1;CSNK2B;GABARAPL1;...
Amino sugar and nucleotide sugar metabolism	-1.80	2.22e-2	38/48 (79.17%)	HEXA;CYB5R3;NAGK;...
Malaria	-1.84	1.46e-2	44/50 (88%)	IL1B;LRP1;HGF;...
Endocytosis	-1.87	1.52e-2	198/252 (78.57%)	LDLR;RAB11FIP5;SNX3;...
Lysosome	-1.91	1.62e-2	115/128 (89.84%)	NPC2;MAN2B1;CLTCL1;...
Protein processing in endoplasmic reticulum	-1.93	1.82e-2	127/171 (74.27%)	SKP1;HSPA1A;PLAA;...
Vibrio cholerae infection	-2.19	0.00e+0	44/50 (88%)	KDELR2;ATP6V0C;SEC61A1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.04uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼